SUPRIYA LIFESCIENCE LTD.
Creating true values that bind global health

Date: January 25, 2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 543434

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: SUPRIYA

Dear Sir/Madam,

Subject: Press Release- Unaudited Financial Results for the quarter and nine months ended December 31, 2024

The Board of Directors of the Company at their Meeting held on January 24, 2025 has inter alia, considered and approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2024.

Please find attached the Press Release with regard to the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024.

Kindly take the same on record and acknowledge the receipt.

Thanking you,

For Supriya Lifescience Limited

SHWETA SHIVDHARI SINGH

Digitally signed by SHWETA SHIVDHARI SINGH
DN: c=IN, o=PERSONAL, pseudonym=5ed61118f9524963913aab8b2dd2f858, 2.5.4.20=7ecd6cc212b10d907bb2883c588d6eb1d1f28d80e13dba2ebd6975df438869e5, postalCode=400097, st=Maharashtra, serialNumber=b696ab674736edaacabe9d4e9a63ae406ea0e6dd83072b0cf6fa56593bffa9dd, cn=SHWETA SHIVDHARI SINGH
Date: 2025.01.25 11:34:50 +05'30'

Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

SUPRIYA LIFESCIENCE LTD.

Press Release for immediate distribution

Supriya Lifescience Q3FY25 PAT Jumps 125% YoY to Rs 46.78 Crore

Mumbai, 25th January 2025: The unaudited financial statements for the Q3FY25 results have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic. The company has spread its business in more than 86 countries across the globe.

Key Consolidated Financial Highlights:

Particulars	Q3 FY25	Q3 FY24
Revenues (in Rs Cr)	185.65	140.07
Gross Profit (in Rs Cr)	123.87	85.45
EBITDA (in Rs Cr)	68.05	44.55
EBITDA Margin	36.66%	31.81%
PAT (in Rs Cr)	46.78	20.79
PAT Margin	25.2%	14.84%
Quarterly EPS (in Rs)	5.82	3.70

Key Highlights for Q3 FY25:

In the third quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 33% year-over-year increase, reaching Rs. 185.65 crore compared to Rs. 140.07 crore in Q3 FY24.

Gross Profit for Q3 FY25 stood at Rs. 123.87 crore, with a growth of 45% compared to Rs. 85.45 crore in Q3 FY24.

EBITDA for Q3 FY25 stood at Rs. 68.05 crore, with an EBITDA Margin of 36.66% , as opposed to an EBITDA of Rs. 44.55 crore in Q3 FY24 with an EBITDA margin of 31.81%. This marks an improvement of 485 bps YoY.

The Profit After Tax (PAT) increased by 125% for Q3 FY25 to Rs 46.78 crore, compared to Rs 20.79 crore in Q3 FY24.

The PAT Margin stood at 25.2% in Q3 FY25, compared to 14.84% in Q3 FY24.

Dr. Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience Ltd, commenting on the results, said, *"Our Q3FY25 results underscore Supriya Lifescience's commitment to delivering value through operational excellence and strategic growth initiatives. The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments. The steady improvement in our EBITDA and PAT margins, reaching 37% and 25% respectively, highlights our ability to maintain profitability while investing in sustainable growth."*

……

Disclaimer Statements in this "Document" describing the company's objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments or circumstances after the date hereof.

About Supriya Lifescience Ltd.:

Supriya Lifescience Ltd., a world-renowned producer of active pharmaceutical ingredients, was founded in 1987. Our cutting-edge facility has certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. The company is headquartered in Mumbai, India, and our facility is located in Khed, District Ratnagiri. Our globally compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA) are supported by robust R&D, eight active CEPs, and fourteen active USDMFs. EHS requirements and ethical principles guide our core business. The company's primary focus is to build intermediates and APIs for innovators and generic firms. We also exclusively collaborate with partners in the capacity of CMOs.